Medis is proud to announce that as of last Friday it has taken control over Breath ltd. Breath is a company legacy Watson acquired when Arrow was acquired back in 2009. Breath business consists of production and supply of inhalers, nebulizers and eye-drops.
All commercial operations related to Breath will from now on be Medis responsibility. Breath´s portfolio consists of the following products: Budesonide, Latanoprost, Latanoprost/Timolol, Salbutamol, Ipratropium, Ipratropium/Albutarol, Ipratropium/Salbutamol, Terbutaline.